Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Relay Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Relay Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RLAY vs CELC, VKTX, DYN: Buyback Yield % Comparison
For the Biotechnology subindustry, Relay Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relay Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Relay Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics (RLAY) has a Buyback Yield % of -10.36 as of Aug. 13, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Relay Therapeutics and its competitors. According to the industry distribution chart, Relay Therapeutics ranks #372 out of 725 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Relay Therapeutics' Buyback Yield % too high?
Relay Therapeutics' current Buyback Yield % is -10.36. Based on the distribution chart, Relay Therapeutics ranks #372 out of 725 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Relay Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Relay Therapeutics' Buyback Yield % compare to CELC and VKTX?
According to the Biotechnology industry distribution chart, Relay Therapeutics ranks #372 out of 725 companies for Buyback Yield %. This places Relay Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Relay Therapeutics and its competitors. Relay Therapeutics's current Buyback Yield % is -10.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relay Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Relay Therapeutics (RLAY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.80, compared to a current price of $20.08 — trading 428.4% above its estimated fair value. The current Buyback Yield % is -10.36. Relay Therapeutics' overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Relay Therapeutics (RLAY), the current Buyback Yield % is -10.36 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relay Therapeutics (RLAY) Overvalued in 2026?
Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued.
The current stock price of $20.08 is trading 428.4% above its estimated GF Value™ of $3.80.
GuruFocus considers Relay Therapeutics to be Significantly Overvalued.
Key valuation signals for RLAY:
Buyback Yield %: -10.36
GF Value™: $3.80 vs. price of $20.08 (428.4% above fair value)
No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
46GF Score
Get the complete analysis for RLAY
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLAY has been successfully added to your 
